logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Trick or Trade

The FDA's Complete Response Letters, Creating Investment Opportunities?

Yesterday, under Today’s Highlights , we posted that the U.S. FDA issued a Complete Response Letter ( CRL ) to Gilead Sciences ( GILD ) with regard to the New Drug Application ( NDA ) for filgotinib - the investigational...

Read More

August 20, 2020

0

What's Going on with Gene Therapy?

Recent Gene Therapy News On August 20, 2020 Audentes Therapeutics , which was taken over by Astellas ( ALPMY ) for over $3 billion, announced that a third patient has passed away in a clinical trial evaluating its gene therapy...

Read More

August 25, 2020

0

Agenus: Could It Be a Resurrection? See Also: Prohost Performing Stocks

Agenus Announced Data from Phase 2 Trials of Balstilimab Agenus ( AGEN ) immuno-oncology company announced that data from two Phase 2 trials of balstilimab alone and in combination with zalifrelimab will be orally presented in at the upcoming European Society...

Read More

September 2, 2020

0

News About Reata Pharmaceuticals

Reata Pharmaceuticals The Positive News  Prohost Biotech's interest in Reata Pharmaceuticals ( RETA ) started when we recognized and appreciated the firm’s goals and its scientific capability. Reata Pharmaceuticals' goal is discovering molecular pathways that regulate cellular metabolism, inflammation and...

Read More

January 19, 2021

0

Sorrento Therapeutics Releases Preclinical Data from STI-1499 and STI-2020 Demonstrating Potent Neutralizing Antibodies Against SARS-CoV-2

Sorrento Therapeutics Preclinical Data of Neutralizing Antibodies Against SARS-CoV-2 In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus. Both STI-1499 and STI-2020 demonstrated protective activities against SARS-CoV-2...

Read More

September 29, 2020

0

SARS-CoV-2 Virus vs The President of the United States

President Trump, the First Lady and COVID-19 Indeed, the complicated, nasty SARS-CoV-2 virus managed to infect President Trump and the First Lady when we were expecting a vaccine to soon be ready to protect the country and the world from...

Read More

October 5, 2020

0

The Reasons for the Immunome, Inc Stock Rally

Immunome, Inc. Immunome, Inc ( IMNM ) announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 (the virus that causes COVID-19) variants, including the South African Variant ( B.1.351 ), in pseudovirus testing.  This...

Read More

February 18, 2021

0

It’s All About Common Sense: Intellia Therapeutics

The Nonsensical Downgrading of Development-Stage Firms Like Intellia Therapeutics It makes no sense to downgrade a development-stage firm such as CRiSPR gene editing IntelliaTherapeutics ( NTLA ) when only based on stopping short of attaining analysts’ expectations with regard to...

Read More

March 9, 2021

0

A New COVID-19 Vaccine is Showing Successful Results. See Also: More Details About the Effective COVID-19 Vaccines

COVID-19 Vaccine Updates Pfizer's ( PFE ) /BioNTech's ( BNTX ) and Moderna's ( MRNA ) COVID-19 vaccines have demonstrated safety at around 95% efficacy.   AstraZeneca ( AZN ) and Oxford University announced today that their COVID-19 vaccine was...

Read More

November 23, 2020

0

News About Reata Pharmaceuticals

Reata Pharmaceuticals The Positive News  Prohost Biotech's interest in Reata Pharmaceuticals ( RETA ) started when we recognized and appreciated the firm’s goals and its scientific capability. Reata Pharmaceuticals' goal is discovering molecular pathways that regulate cellular metabolism, inflammation and...

Read More

January 19, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 3
  • 4
  • 5
  • ...
  • 16
  • 17
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy